Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)GlobeNewsWire • 03/10/20
Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price GainsSeeking Alpha • 03/05/20
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China RegionGlobeNewsWire • 02/24/20
Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?Zacks Investment Research • 12/20/19
Why One Analyst Still Sees Almost 200% Upside in Paratek Pharma, Even After Its Huge Gain24/7 Wall Street • 12/19/19
BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 202024/7 Wall Street • 12/19/19
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/13/19
Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/05/19
Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract InfectionsGlobeNewsWire • 10/31/19
Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and PneumoniaGlobeNewsWire • 10/17/19
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019GlobeNewsWire • 09/25/19
Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/04/19
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin InfectionsGlobeNewsWire • 08/30/19
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare ConferenceGlobeNewsWire • 08/26/19